The case for & against
Bull & Bear analysis
Bullish
Abbott Laboratories (NYSE: ABT) is a leading global healthcare company specializing in the discovery, development, manufacture, and sale of a wide range of healthcare products. Its diverse portfolio includes diagnostics, medical devices, nutrition, and branded generic pharmaceuticals, positioning it strongly in both developed and emerging markets. The company is currently benefiting from themes of increasing healthcare demand, innovation in medical technologies, and nutritional products aimed at improving patient outcomes.
Bull says
- ↑Q2 revenue $10.5B (+4.8% YoY) accelerated to mid-single digits
- ↑Declared 410th consecutive $0.63 dividend, yielding 0.88%
- ↑Medical Devices segment grew 9.0% in Q2, driven by cardiovascular care
- ↑Adjusted gross margin expanded to 58.0% (+100bps YoY)
- ↑Amulet 360 and Libre Duo launches in next 12 months as catalysts
- ↑Strong quality profile and high dividend yield support resilience
Bear says
- ↓Weak profitability factors and low earnings yield pressure returns
- ↓Declining analyst revisions reflect lower earnings expectations
- ↓High stock volatility and negative momentum raise investment risks
- ↓U.S. procedure volume declines could dampen device demand
- ↓Intensifying competition in diabetes care and electrophysiology threatens share
- ↓Valuation risk elevated amid macro uncertainty and segment volatility
Investment themes with ABT
High Dividend Yield↑ +0.32%
Companies paying above-average dividends
AVGO · JPM · XOM
Quality↑ +0.54%
Companies with strong fundamentals and stability
NVDA · AAPL · MSFT
Medical Devices↑ +0.12%
Devices and instruments for medical treatment
ISRG · ABT · SYK
Earnings Call · Q4 2023 · Mgmt. Guidance
Updated 01-24-2025neutral
Transcript signals
Read full transcript analysis ›